Us 8158616 b2 baricitinib synthesis?

Synthesis of Baricitinib and Its Patented Variations

Baricitinib, a potent and selective inhibitor of Janus kinase (JAK), is a medication used to treat various inflammatory and autoimmune diseases. The synthesis of baricitinib is a multi-step process that involves several chemical transformations.

The Patented Process of Baricitinib Synthesis

The patented process for synthesizing baricitinib is detailed in US Patent 8158616 B2, owned by Eli Lilly and Company. According to the patent, the synthesis involves the reaction of a benzylamine with a sulfonamide-containing compound to form an intermediate compound. This intermediate is then subjected to a series of chemical transformations, including oxidation and reduction reactions, to produce baricitinib.

[1] US Patent 8158616 B2 (2012)

Chemical Synthesis and Variations

The chemical synthesis of baricitinib involves the use of various reagents and conditions to produce the final product. The patented process described in US Patent 8158616 B2 provides a specific route for synthesizing baricitinib, but other variations and modifications may exist.

Comparison with Other JAK Inhibitors

Baricitinib is a member of a class of medications known as JAK inhibitors, which also includes other drugs such as tofacitinib and ruxolitinib. Comparison with other JAK inhibitors can provide insights into the relative advantages and disadvantages of baricitinib.

Regulatory Status and Exclusivity

Baricitinib has received approval from regulatory authorities worldwide for the treatment of various inflammatory and autoimmune diseases. The patent for baricitinib is ongoing, but its exclusivity is subject to expiry.

Potential Biosimilar Entrants

The potential for biosimilars to enter the market before patent expiry is a topic of interest for pharmaceutical companies and regulatory authorities. Biosimilars can offer cost-saving options for patients and payers, but their development and approval processes are complex and challenging.

Clinical Data and Patient Concerns

Clinical trials have demonstrated the efficacy and safety of baricitinib for various indications, including rheumatoid arthritis. However, patients may have concerns about the potential side effects and risks associated with the medication.

Regulatory Approval and Pricing

Regulatory authorities worldwide have approved baricitinib for various indications. Pricing and reimbursement decisions are influenced by various factors, including clinical effectiveness, cost-effectiveness, and market competition.

Sources:

[1] US Patent 8158616 B2 (2012) - Eli Lilly and Company - Baricitinib Synthesis